A current FDA‐approved therapy for metastatic UM includes Tebentafusp, a bispecific T‐cell engager that recruits CD3+ T cells to gp100‐expressing melanoma and has shown modest survival benefits (Hassel et al. 2023; Nathan et al. 2021). This evidence concerns the gene PMEL and melanoma.